MedDataX Logo

Detection of Helicobacter Pylori in Ulcerative Colitis Patients

NCT ID: NCT03172000

Last Updated: 2017-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases in humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several bacterial and viral agents may have a role in the aetiology of IBD. In theory, H. pylori infection could be involved in IBD by inducing alterations in gastric and/or intestinal permeability or by causing immunological derangements resulting in absorption of antigenic material and autoimmunity via various immunological pathways.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colonoscopy and biopsy

IBD patients

Group Type ACTIVE_COMPARATOR

Colonoscopy and biopsy

Intervention Type DIAGNOSTIC_TEST

Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.

Colonoscopic biopsy

Non IBD patients colonoscopic biopsy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colonoscopy and biopsy

Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* newly diagnosed ulcerative colitis

Exclusion Criteria

* Other diagnosis
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Loai Mansour, MD

Role: PRINCIPAL_INVESTIGATOR

Tanta University Faculty of Medicine

Ferial El-kalla, MD

Role: PRINCIPAL_INVESTIGATOR

Tanta university Faculty of Medicine

Abdelrahman Kobtan, MD

Role: STUDY_DIRECTOR

Tanta University Faculty of Medicine

Hanan Soliman, MD

Role: STUDY_DIRECTOR

Tanta University Faculty of Medicine

Sherief Abd-Elsalam, MD

Role: STUDY_CHAIR

Tanta University Faculty of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta university - faculty of medicine

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sherief Abd-Elsalam, MD

Role: CONTACT

Phone: 00201147773440

Email: [email protected]

sherief Abd-Elsalam, Consultant

Role: CONTACT

Phone: 00201147773440

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sherief M Abdelsalam, lecturer

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IBD Helicobacter

Identifier Type: -

Identifier Source: org_study_id